In Vitro Activity of Ramoplanin against Clostridium difficile, Including Strains with Reduced Susceptibility to Vancomycin or with Resistance to Metronidazole

AUTOR(ES)

Peláez, T.

FONTE

American Society for Microbiology

RESUMO

We evaluated the in vitro activity of ramoplanin, an antimicrobial compound that inhibits cell wall synthesis by acting at the level of lipid intermediate formation, against Clostridium difficile. We included strains with reduced susceptibilities to vancomycin (vancomycin-intermediate [Vani] strains) or with resistance to metronidazole (Mtzr), in order to assess the potential utility of ramoplanin for the treatment of C. difficile-associated diarrhea. We tested the activity of ramoplanin against a total of 105 nonduplicate clinical isolates of toxigenic C. difficile, including 8 Vani isolates and 6 Mtzr isolates, obtained from our laboratory. Ramoplanin was active against all strains tested at concentrations ranging from 0.03 to 0.5 μg/ml (MICs at which 50 and 90% of isolates were inhibited, 0.25 μg/ml; geometric mean MIC, 0.22 μg/ml). All isolates, independently of their levels of susceptibility to vancomycin or metronidazole, were considered susceptible to ramoplanin (MICs, ≤0.5 μg/ml).

Documentos Relacionados

• Reassessment of Clostridium difficile Susceptibility to Metronidazole and Vancomycin
• Activity of AZD2563, a Novel Oxazolidinone, against Staphylococcus aureus Strains with Reduced Susceptibility to Vancomycin or Linezolid
• Alterations in human fecal flora, including ingrowth of Clostridium difficile, related to cefoxitin therapy.
• In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms.
• In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile.